Andrew Kuykendall, MD, Moffitt Cancer Center, Tampa, FL, discusses his recent publication reviewing the challenges and treatment options for patients with hydroxyurea-resistant polycythemia vera (PV). Dr Kuykendall highlights that, although hydroxyurea is still used in first-line PV treatment, a greater number of disease-modifying agents are becoming available which treat the disease in a distinct way, including interferon and JAK inhibitors. There is a need for clinicians to consider the unique situation of each patient in order to choose the best therapeutic option for the individual. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

0 Comments

Up next

Autoplay

Overcoming Challenges Made Easy with Elavil: An Insightful Overview

0 Views . 08/29/25 Side Effects

Please note that if you are under 18, you won't be able to access this site.

Up next

Challenges and options for patients with hydroxyurea-resistant PV

Up next

Language